FDA Catalyst Intelligence · Biotech Investors
PDUFA Pulse
MONDAY · JULY 20, 2026
PoA = directional probability-of-approval estimate; not FDA guidance. Weekend target dates can produce an earlier Friday or subsequent Monday public announcement.
► The Board · Jul 20 – Aug 17
CELC PRINTED EARLY. TWO ADCOMS NOW DEFINE LATE JULY.

FDA approved REVTORPYK on July 14, three days before its target date. MNKD’s July 26 weekend clock is next.

Then four different regulatory questions land inside two days: CAPR’s AdCom and OTLK’s Class 1 action on July 29, followed by VTRS and REPL’s AdCom on July 30. The date compression is real. The risk is not uniform.

 
► Live FDA Board
Date Ticker / Event Setup / Risk PoA
Sun
Jul 26
MNKD
FUROSCIX ReadyFlow Autoinjector
 Delivery sNDA
Device / execution		 73%
Wed
Jul 29
CAPR
deramiocel CTGTAC
PDUFA Aug 22
 Class 2 / AdCom
Cardiac evidence; CMC status undisclosed		 ADCOM
Wed
Jul 29
OTLK
LYTENAVA / wet AMD
 Post-appeal Class 1
Label / closeout		 85%
Thu
Jul 30
VTRS
MR-100A-01 weekly patch
 505(b)(2) NDA
Efficacy / BMI / adhesion		 90%
Thu
Jul 30
REPL
RP1 + nivolumab CTGTAC
 Post-2nd-CRL Class 1
Evidence adequacy		 ADCOM
Sun
Aug 2
REPL
RP1 + nivolumab / melanoma
 Post-2nd-CRL Class 1
Evidence adequacy		 19%
Wed
Aug 5
MRNA
MFLUSIVA / mRNA-1010
 Post-AdCom BLA
Age-split pathway		 85%
Thu
Aug 13
LNTH
MK-6240 tau PET imaging
 Fast Track NDA
Performance / label		 88%
Mon
Aug 17
BMY
iberdomide + dara/dex
 Priority / Breakthrough
MRD pathway		 79%
Board dates reflect current company, SEC and FDA disclosures. PoAs are PDUFA Pulse editorial estimates, rounded to whole numbers.
 
► Board Delta · Since Last Monday
✓ CELC / REVTORPYK — APPROVED EARLY · JUL 14
FDA approved gedatolisib with fulvestrant, with or without palbociclib, for adults with HR-positive/HER2-negative locally advanced or metastatic breast cancer without a detected PIK3CA mutation after progression following at least one line of endocrine therapy in the metastatic setting. Both regimens made the label.
✓ MRK / KEYTRUDA + PADCEV — CORRECTION: APPROVED JUL 10
Last week’s Aug. 17 entry was stale. FDA had already approved KEYTRUDA and KEYTRUDA QLEX, each with Padcev, as perioperative treatment for adults with muscle-invasive bladder cancer. Both Aug. 17 MRK rows leave the live calendar.
→ CAPR — NOW FRONT BOARD · ADCOM JUL 29
FDA’s CTGTAC will review deramiocel for cardiomyopathy in Duchenne muscular dystrophy ahead of the Aug. 22 PDUFA date. The Class 2 response adds randomized Phase 3 HOPE-3 data after the 2025 CRL requested additional clinical evidence.
→ BMY — AUG 17 NOW FRONT BOARD
Iberdomide plus daratumumab and dexamethasone is under Priority Review and has Breakthrough Therapy designation. The filing rests on a planned MRD-negativity analysis from randomized Phase 3 EXCALIBER-RRMM while PFS follow-up continues.
✓ OTHER FDA MOVES
FDA approved an at-home starting regimen for LEQEMBI IQLIK on July 13, converted RETEVMO’s tumor-agnostic indication to traditional approval on July 14, and approved LIPFENDRA as the first oral PCSK9 inhibitor later in the week.
 
► Risk Types On This Board
DEVICE / FORMAT EXECUTION
The active drug is familiar; delivery performance, pharmacokinetics, usability, manufacturing and labeling drive MNKD.
CLASS 1 CLOSEOUT AFTER DISPUTE RESOLUTION
OND concluded that substantial evidence has been established for OTLK and directed final labeling. Residual risk is labeling, application closeout or an undisclosed issue.
ADCOM / EVIDENCE ADEQUACY
CAPR added randomized Phase 3 data, including a prespecified cardiac endpoint. REPL is in a complete Class 1 response cycle after two CRLs centered on effectiveness.
AGE-SPLIT APPROVAL PATH
MRNA seeks full approval in adults 50–64 and accelerated approval in adults 65 and older. The AdCom voted 9–0 in each age group, but the votes are non-binding.
MRD-BASED REVIEW
BMY’s filing uses MRD negativity as the current efficacy read while EXCALIBER-RRMM continues toward PFS. The undisclosed treatment-effect magnitude keeps this from being routine.
 
► Top Two Setups
MNKD$MNKD · ReadyFlowSun Jul 26  PoA 73%
DELIVERY-FORMAT sNDA · DEVICE / EXECUTION

ReadyFlow would deliver an IV-equivalent diuretic dose using an 80 mg/mL subcutaneous furosemide formulation in under 10 seconds as an alternative to the approved FUROSCIX On-body Infusor. The drug thesis is familiar; the new binary is the autoinjector package.

Filed indication: Edema in adults with chronic heart failure or chronic kidney disease.
FDA question: Does the autoinjector deliver the established dose reliably, safely and with acceptable device, usability, manufacturing and labeling controls?
If approved: The read-through shifts to adoption, reimbursement and whether the faster format expands use.
If CRL: Separate device, human-factors, PK, manufacturing and label deficiencies from the underlying furosemide thesis.
What can change: The target remains Sunday, but FDA action or the company announcement could arrive Friday or Monday.
CAPR$CAPR · deramiocelAdCom Jul 29
PDUFA AUG 22 · CLASS 2 RESUBMISSION

The 2025 CRL said the application did not provide substantial evidence for cardiomyopathy in Duchenne muscular dystrophy. FDA said HOPE-2 had been designed around neuromuscular function, not cardiomyopathy, and recommended an adequate controlled study focused on cardiac outcomes.

CAPR returned with randomized, double-blind, placebo-controlled HOPE-3: the PUL v2.0 primary endpoint reached p=0.029 and the prespecified LVEF cardiac endpoint reached p=0.041.

Filed indication: Treatment of cardiomyopathy in Duchenne muscular dystrophy.
FDA question: Does the full package provide substantial evidence of clinically meaningful cardiac benefit with acceptable risk?
If approved: Read the label for population and cardiac-disease limits, then separate regulatory success from the U.S. distribution dispute.
If CRL: Did cardiac evidence remain insufficient, or did undisclosed CMC/facility or other deficiencies remain open? The public CRL does not identify the specific CMC issues.
What can change: Briefing materials, the July 29 vote and the Aug. 10 distribution hearing. Capricor says litigation has not changed the FDA timeline.
 
► Failure Mode Of The Week · Same Committee, Different Evidence Problem

CAPR goes to CTGTAC on July 29. REPL follows on July 30.

CAPR’s question is whether the randomized Phase 3 package repairs a cardiomyopathy-specific substantial-evidence CRL.

REPL’s question is whether its complete Class 1 response overcomes FDA’s objections concerning response reliability, patient heterogeneity, historical-control interpretation and RP1’s contribution to the combination. The committee name is the same. The evidentiary posture is not.

 
► If This Fails, What Broke?
MNKDDelivery, human factors, PK, manufacturing or label—not the established furosemide thesis?
CAPRDid HOPE-3 fail to close the cardiomyopathy gap, or did undisclosed CMC/facility or other deficiencies remain?
OTLKDid final labeling or closeout fail after OND resolved the efficacy dispute, or did a new issue emerge?
VTRSContraceptive efficacy, BMI-limited population, adhesion, PK or safety language?
REPLDid the response overcome objections on reliability, heterogeneity, historical controls and RP1’s contribution?
MRNAOlder-adult accelerated pathway, safety/label negotiations or manufacturing despite two 9–0 votes?
LNTHSensitivity/specificity, image interpretation or the proposed diagnostic label?
BMYWas MRD insufficient for the proposed pathway or regimen, or did effect size, safety or execution fail?
 
► Resolved / Removed
× CELC / REVTORPYK — APPROVED
FDA acted July 14, three days before the July 17 target. Both the doublet and triplet are on the approved label.
× MRK / KEYTRUDA + PADCEV — APPROVED / STALE DATE REMOVED
The July 10 approval eliminates both tracker rows that still showed Aug. 17.
 
► Weekly Posture

The board is more compressed and more public now: two AdComs expose two different evidence debates on consecutive days.

Resolved: CELC / REVTORPYK; MRK / KEYTRUDA and KEYTRUDA QLEX plus Padcev correction.

Live: MNKD → CAPR AdCom / OTLK → VTRS / REPL AdCom → REPL → MRNA → LNTH → BMY.

Highest-drama name: REPL remains the lowest-PoA setup, but CAPR is the most important new addition because its randomized Phase 3 repair package now faces a public test.

That is the queue.
Forward this to someone treating CAPR and REPL as the same AdCom setup.

Informational only · Not investment advice · Biotech carries risk of total loss

Keep Reading

© 2026 PDUFA Pulse.
beehiivPowered by beehiiv